实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2014年
1期
78-80
,共3页
胰腺癌%吉西他滨%替吉奥胶囊%生存质量
胰腺癌%吉西他濱%替吉奧膠囊%生存質量
이선암%길서타빈%체길오효낭%생존질량
Pancreatic cancer%Gemcitabine%S-1 capsule%Life quality
目的:探讨胰腺癌根治术后行吉西他滨联合替吉奥胶囊化疗的临床疗效。方法将60例胰腺癌根治术后患者随机分为给予吉西他滨联合替吉奥胶囊化疗的观察组和吉西他滨联合紫杉醇化疗的对照组,观察2组患者的生活质量、疗效、不良反应及肿瘤内分泌指标。结果观察组生活质量化疗后2周(81.1±9.5)、4周(84.8±10.4)、8周(90.3±12.9)、12周(95.2±13.8),sFlt-1水平(178.3±23.1),平均生存时间[(32.7±6.5)月]、2年生存率(66.7%)、3年生存率(40.0%)均明显高于对照组;心、肝、肾功能损害发生率(20.0%)、VEGF水平(63.2±9.5)均低于对照组(P<0.05)。结论吉西他滨联合替吉奥胶囊化疗能够改善胰腺癌根治术后患者的生活质量,具有积极的临床价值。
目的:探討胰腺癌根治術後行吉西他濱聯閤替吉奧膠囊化療的臨床療效。方法將60例胰腺癌根治術後患者隨機分為給予吉西他濱聯閤替吉奧膠囊化療的觀察組和吉西他濱聯閤紫杉醇化療的對照組,觀察2組患者的生活質量、療效、不良反應及腫瘤內分泌指標。結果觀察組生活質量化療後2週(81.1±9.5)、4週(84.8±10.4)、8週(90.3±12.9)、12週(95.2±13.8),sFlt-1水平(178.3±23.1),平均生存時間[(32.7±6.5)月]、2年生存率(66.7%)、3年生存率(40.0%)均明顯高于對照組;心、肝、腎功能損害髮生率(20.0%)、VEGF水平(63.2±9.5)均低于對照組(P<0.05)。結論吉西他濱聯閤替吉奧膠囊化療能夠改善胰腺癌根治術後患者的生活質量,具有積極的臨床價值。
목적:탐토이선암근치술후행길서타빈연합체길오효낭화료적림상료효。방법장60례이선암근치술후환자수궤분위급여길서타빈연합체길오효낭화료적관찰조화길서타빈연합자삼순화료적대조조,관찰2조환자적생활질량、료효、불량반응급종류내분비지표。결과관찰조생활질양화료후2주(81.1±9.5)、4주(84.8±10.4)、8주(90.3±12.9)、12주(95.2±13.8),sFlt-1수평(178.3±23.1),평균생존시간[(32.7±6.5)월]、2년생존솔(66.7%)、3년생존솔(40.0%)균명현고우대조조;심、간、신공능손해발생솔(20.0%)、VEGF수평(63.2±9.5)균저우대조조(P<0.05)。결론길서타빈연합체길오효낭화료능구개선이선암근치술후환자적생활질량,구유적겁적림상개치。
Objective To study clinical efficacy of gemcitabine combined with S-1 capsule for pancreatic cancer patients treated with radical resection .Methods 60 cases of pancreatic cancer patients who received radical resection were randomly di -vided into the observation group ( given gemcitabine combined with S-1 capsule ) and the control group ( given gemcitabine and pa-clitaxel).Quality of life,efficacy,adverse reactions and tumor endocrine index of the 2 groups were observed.Results In the ob-servation group,quality of life of were(81.1 ±9.5),(84.8 ±10.4),(90.3 ±12.9)and(95.2 ±13.8)2,4,8 and 12 weeks after chemotherapy,respectively;and sFlt-1 level was (178.3 ±23.1),average survival time was (32.7 ±6.5) months;2-and 3-year survival rates were 66.7%and 40.0%.The above items of the observation group were significantly higher than those of the con -trol group.Incidence of heart,liver and kidney function damage (20.0%) and VEGF level (63.2 ±9.5)were lower than those of the control group .Conclusion Gemcitabine combined with S-1 capsule can improve life quality of pancreatic cancer patients treated with radical resection ,and it has positive clinical value .